Candel Therapeutics(CADL) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Research and Development Expenses: Research and development expenses were 5.0 million for the second quarter of 2024. The increase was primarily due to an increase in manufacturing costs in support of the Company's CAN- 2409 programs, partially offset by a decrease in employee-related expenses, which was driven primarily from a reduction in stock-based compensation expense. Research and development expenses included a non-cash stock compe ...